<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0024">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Omrani</surname>
    <given-names>A. S.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Saad</surname>
    <given-names>M. M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Baig</surname>
    <given-names>K.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bahloul</surname>
    <given-names>A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Abdul-Matin</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Alaidaroos</surname>
    <given-names>A. Y.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Almakhlafi</surname>
    <given-names>G. A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Albarrak</surname>
    <given-names>M. M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Memish</surname>
    <given-names>Z. A.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Albarrak</surname>
    <given-names>A. M.</given-names>
   </name>
  </person-group> (
  <year>2014</year>). 
  <article-title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study</article-title>. 
  <source>
   <italic>The Lancet. Infectious Diseases</italic>
  </source>, 
  <volume>14</volume>(
  <issue>11</issue>), 
  <fpage>1090</fpage>â€“
  <lpage>1095</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70920-X</pub-id>
  <pub-id pub-id-type="pmid">25278221</pub-id>
 </mixed-citation>
</ref>
